Back to Agenda
Session 7C: The Integrated Delivery Network: An Evolving Customer for Medical Affairs Engagement and Support
Session Chair(s)
Kevin Charles Henderson, PharmD, MBA
Executive Director, Hematology US Medical Affairs
Gilead Sciences, United States
The growth and importance of Integrated Delivery Networks (IDNs) are redefining how the biopharmaceutical industry engages its external stakeholders. Significant business challenges have emerged around how best to address IDNs’ unique needs, including how companies structure and deploy their medical and scientific field resources. This session will provide an overview of IDNs, but will focus on the role of medical affairs with these customers, both now and in the future. The format will be primarily an audience/moderator-driven discussion with two panel IDN biopharmacteutical industry experts.
Learning Objective : At the conclusion of this session, participants should be able to:- Describe the current IDN landscape in the US and their key business challenges
- Discuss the expanding role of IDNs within the broader US health care system and its implications on health care delivery, access to medicines, and reimbursement
- Compare and contrast the pharmaceutical industry’s traditional versus novel approaches to interacting with IDNs and critical success factors for future engagement
Speaker(s)
Panelist
Michael Dubroff, MD
Genentech, Inc., A Member of the Roche Group, United States
Panelist
James Stephen Dodge, PharmD, MBA
Merck & Co., Inc., United States
Executive Director, Medical Affairs Health Systems
Have an account?